Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF IRANIAN MEDICINE   APRIL 2015 , Volume 18 , Number 4; Page(s) 223 To 227.
 
Paper: 

A COMPARATIVE APPROACH BETWEEN HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGY AND DNA VACCINATIONS FOR RABIES

 
DOI: 

015184/AIM.006

 
Author(s):  BORHANI KIANDOKHT, AJORLOO MEHDI, BAMDAD TARAVAT, MOZHGANI SAYED HAMID REZA, GHADERI MOSTAFA, GHOLAMI ALIREZA*
 
* WHO COLLABORATING CENTER FOR REFERENCE AND RESEARCH ON RABIES, PASTEUR INSTITUTE OF IRAN, 12 FARVARDIN ST., TEHRAN, IRAN
 
Abstract: 

BACKGROUND AND AIM: Rabies is a widespread neurological zoonotic disease causing significant mortality rates, especially in developing countries. Although a vaccine for rabies is available, its production and scheduling are costly in such countries. Advances in recombinant DNA technology have made it a good candidate for an affordable vaccine. Among the proteins of rabies virus, the Glycoprotein (RVG) has been the major target for new vaccine development which plays the principalrole in providing complete protection against RV challenge. The aim of this study is to produce recombinant RVG which could be a DNA vaccine candidate and to evaluate the efficiency of this construct in a prime-boost vaccination regimen, compared to commercial vaccine.
METHODS: Cloning to pcDNA3.1 (+) and expression of rabies virus glycoprotein gene in BSR cell line were performed followed by SDS-PAGE and Western blot analysis of the expressed glycoprotein. The resulting genetic construct was used as a DNA vaccine by injecting 80
mg of the plasmid to MNRI mice twice. Prime-Boost vaccination strategy was performed using 80 mg plasmid construct as prime dose and the second dose of an inactivated rabies virus vaccine. Production of rabies virus neutralizing antibody (RVNA) titers of the serum samples were determined by RFFIT.
RESULTS: In comparisons between heterologous prime-boost vaccination strategy and DNA vaccinations, the potency of group D that received Prime-Boost vaccine with the second dose of pcDNA3.1 (+)-Gp was enhanced significantly compared to the group C which had received pcDNA3.1 (+)-Gp as first injection.
CONCLUSION: In this study, RVGP expressing construct was used in a comparative approach between Prime-Boost vaccination strategy and DNA vaccination and compared with the standard method of rabies vaccination. It was concluded that this strategy could lead to induction of acceptable humoral immunity.

 
Keyword(s): DNA VACCINE, PASTEUR VIRUS, PRIME, BOOST, RABIES
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
 
+ Click to Cite.
APA: Copy

BORHANI, K., & AJORLOO, M., & BAMDAD, T., & MOZHGANI, S., & GHADERI, M., & GHOLAMI, A. (2015). A COMPARATIVE APPROACH BETWEEN HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGY AND DNA VACCINATIONS FOR RABIES. ARCHIVES OF IRANIAN MEDICINE, 18(4), 223-227. https://www.sid.ir/en/journal/ViewPaper.aspx?id=446028



Vancouver: Copy

BORHANI KIANDOKHT, AJORLOO MEHDI, BAMDAD TARAVAT, MOZHGANI SAYED HAMID REZA, GHADERI MOSTAFA, GHOLAMI ALIREZA. A COMPARATIVE APPROACH BETWEEN HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGY AND DNA VACCINATIONS FOR RABIES. ARCHIVES OF IRANIAN MEDICINE. 2015 [cited 2021October22];18(4):223-227. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=446028



IEEE: Copy

BORHANI, K., AJORLOO, M., BAMDAD, T., MOZHGANI, S., GHADERI, M., GHOLAMI, A., 2015. A COMPARATIVE APPROACH BETWEEN HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGY AND DNA VACCINATIONS FOR RABIES. ARCHIVES OF IRANIAN MEDICINE, [online] 18(4), pp.223-227. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=446028.



 
  pdf-File
Yearly Visit 83
 
 
Latest on Blog
Enter SID Blog